Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Bio-Rad Laboratories Inc (BIO)

NYSE
Currency in USD
Disclaimer
300.45
+0.01(+0.00%)
Closed
After Hours
300.41-0.04(-0.01%)

BIO Comments

340 first
250 next
🚀 vs ⬇️ ?
🚀🚀🚀🚀🚀
🚀
I don't know the company, just came to say: That's the name of a company that could start a zombie apocalypse. 😅
why?
Going to drop by shrinking rev and eps
Sold before the crazy beat..
Massively undervalued!
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
Incredible earnings! Come on in now
To the moon!!!!!
ATTENTION! READ HERE "As of August 2020, Bio-Rad had 37% ownership of Sartorius, and shares of Sartorius have increased about a hundredfold since Bio-Rad first invested in the company in 2003. In the early 2000s, Bio-Rad continued increasing its share of Sartorius, and has booked large (unrealized) gains on the investment since that time. With the Sartorius stake accounting for approximately half of the firm’s valuation, the investment has generated significant value for shareholders. We believe this is relevant in an evaluation of Bio-Rad’s stewardship, as current CEO Norman Schwartz has led the company since 2003, the year of the first investment in Sartorius, and oversaw the increase of the investment in subsequent years."  Morningstar
underestimated stock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.